FitnessLifeMag · Evidence-focused research
Prepare a complete medication review, understand cognitive side-effect evidence and avoid unsafe self-directed changes.
By Biraj Health Care · Editorial research · Evidence checked October 2026
Educational information. New, progressive or function-limiting cognitive changes deserve clinical assessment. Sudden confusion or stroke signs need immediate medical help.
On this page
- Medicines and memory: review, do not abruptly stop
- Sedation, anticholinergic effects and indirect contributors
- Include products that are easy to overlook
- What deprescribing evidence actually shows
- Prepare an individualized review
- Worked example: a new sleep aid
- Prevent errors while respecting independence
- Interactions and follow-up
- Use a timeline and an explicit benefit–risk decision
- Common questions
- Related guides
- Evidence and scope
- Research sources
Medicines and memory: review, do not abruptly stop
Medicines and combinations can affect attention, alertness or cognition, especially in older adults or people with multiple conditions. That is a reason for an individualized review, not an instruction to stop treatment. A medicine may be necessary, and symptoms can have several causes.
Bring all prescription, over-the-counter and supplement products to a clinician or pharmacist. If confusion begins suddenly, obtain urgent assessment rather than waiting for a routine review.
Sedation, anticholinergic effects and indirect contributors
Some products cause sleepiness, making information harder to take in. Others have anticholinergic properties, affecting acetylcholine signalling. The combined exposure is sometimes called anticholinergic burden. The total pattern matters more than recognizing one drug name.
Illness, sleep disruption, pain and the reason a medicine was prescribed can also affect cognition. An association between a drug and decline may partly reflect these factors, so it does not prove that stopping that medicine restores memory.
NIA clinical guidance emphasizes reviewing sedatives, anticholinergics and other potentially contributing products, alongside safe administration. A professional weighs benefit, risk and alternatives.
Include products that are easy to overlook
| Item to bring | Why it matters | Helpful detail |
|---|---|---|
| Prescription treatments | Dose, indication and interactions. | Actual use, not only the printed list. |
| Allergy or cold products | Some can be sedating or anticholinergic. | Exact ingredient and frequency. |
| Sleep products | Next-day alertness and combinations. | Timing and any extra doses. |
| Bladder, pain or muscle-relaxing treatments | Potential cognitive or safety contributions. | Benefits, side effects and start date. |
| Herbs and nutrient blends | Interactions and duplicate ingredients. | Complete label and serving. |
| Alcohol or other substances | Effects on alertness, sleep and interactions. | Honest amount and pattern. |
This is a review checklist, not a list of treatments that everyone should discontinue.
What deprescribing evidence actually shows
A 2023 Cochrane review included three trials and 299 participants, with cognitive outcomes assessed after one to three months. Evidence was very low certainty and insufficient to establish the cognitive benefits of anticholinergic-reduction interventions. Safety outcomes were not investigated adequately.
This does not invalidate medicine review. It means the claim that reducing burden will reliably reverse cognition is stronger than trial evidence supports. Review can still be appropriate for adverse effects, interactions, falls, treatment needs and practical safety.
NICE guidance encourages considering alternatives and minimizing burden where appropriate, while noting uncertainty about which burden scale is best. A number from an online calculator should not determine treatment alone.
Prepare an individualized review
For each product, note the indication, actual dose and timing, start date, recent changes, benefits and suspected problems. Include missed or duplicated doses. Symptoms after a change are informative, but timing alone does not prove causation.
Ask: Is this treatment still needed? Could its dose or timing contribute? Are there interactions or safer alternatives? If a change is suitable, who supervises it, what is the taper if needed, and what should be monitored? How will return of the treated condition be managed?
Do not abruptly stop medicines with withdrawal or rebound risks. A clinician-led plan may change one thing at a time and arrange follow-up. This article cannot provide a personal taper, replacement or dose.
Worked example: a new sleep aid
An older adult feels more drowsy and forgetful after adding an over-the-counter night product while taking several prescriptions. Instead of assuming dementia or simply adding a stimulant, bring the exact night-product label and all medicines to a pharmacist or clinician.
The review considers ingredients, timing, interactions, sleep symptoms and other medical causes. A safe change may be appropriate, but the person still needs follow-up if symptoms persist. The example illustrates a process rather than diagnosing every similar case.
If there are sudden marked confusion, inability to wake, breathing problems or other acute concerning symptoms, seek urgent help rather than conducting a home experiment.
Prevent errors while respecting independence
Ask whether the person can understand and follow the regimen reliably. A simpler schedule, pharmacist-prepared packaging or reminders may help when suitable. Some medicines have special storage or administration rules, so not every product belongs in an ordinary pill organizer.
If doses are being duplicated or missed, arrange professional advice and appropriate support. Involve the person and avoid hidden changes to treatment. A cognitive label alone does not determine decision-making capacity or who may manage medicines.
Keep an updated list available for appointments and emergency care. Agree who will update it after changes so outdated versions do not circulate.
Interactions and follow-up
NCCIH highlights ginkgo–warfarin concerns. Vitamins and herbs are part of medication reconciliation, not an exempt category. Quality documentation does not remove interaction risk or prove cognitive benefit.
After a change, record whether the suspected side effect, original condition and daily function improve or worsen. If symptoms remain, consider broader assessment rather than attributing everything to the medicine.
Read brain supplements, sleep and assessment; return to the pillar for context.
Use a timeline and an explicit benefit–risk decision
For each product, record its name, reason for use, start date, recent dose or timing changes and the change in alertness or function. Include occasional sleep aids, allergy products, alcohol and supplements. A symptom beginning after a change is a clue, not proof of causation; illness and other treatments may have changed at the same time.
Ask which medicine is essential, what benefit it provides, whether a safer alternative exists and what should be monitored if a clinician changes it. The best plan may be to continue, adjust, substitute or carefully reduce a product. There is no universal rule that every medicine on a burden list must be stopped.
Agree on who coordinates changes when several prescribers are involved. Record the plan in understandable language and arrange follow-up for symptoms, function and the original condition. Withdrawal or return of the treated problem can complicate interpretation, which is why self-directed stopping or tapering is unsafe. A lower burden score alone is not the final patient outcome.
Common questions
Should I stop an anticholinergic medicine?
Only after an individualized professional review and safe plan.
Does reducing burden guarantee cognitive recovery?
No. Trial evidence is uncertain, though review may still be appropriate.
Do herbs need to be listed?
Yes. Include every product, amount and frequency, including over-the-counter items.
Evidence and scope
FitnessLifeMag’s editorial review prioritises official health guidance, systematic reviews and human trials. Sources were checked in October 2026. Positive, mixed and null findings are distinguished, with limits on population, outcomes and everyday function.
This is a focused review, not an exhaustive systematic review or independent clinician assessment. Some research was accessible as an abstract rather than full text. It does not independently verify commercial products. Individual care and local treatment availability require professional advice.